Australia Proposes Public Disclosure of Medical Device Review Information; Consultation Window Closes 2 October 2026

Core Content

What Australia is changing: whether information can be shared. On 13 August 2026, the Therapeutic Goods Administration (TGA) opened a public consultation. The deadline is 2 October 2026—approximately seven weeks. The proposal can be summarized in one sentence: after a post-market review or investigation is completed, more information related to device safety, quality, performance and use would be disclosed to the public. Section 61 of the Therapeutic Goods Act 1989 currently permits publication only in limited circumstances. This consultation asks whether that power should be expanded and, if so, to what extent.

Boundary: This is a proposal and consultation, not law in force. For companies selling devices in Australia today, compliance requirements have not changed by a single word.

Who Is Directly Affected: The Entry in the Register

In Australia, a device is placed on the market by being included in the Australian Register of Therapeutic Goods (ARTG). The applicant for that entry is the Australian sponsor. If the proposal is implemented, the first object of disclosure would not be the overseas factory, but the entry in the ARTG and the sponsor and manufacturer names attached to it.

For Chinese companies, two identities must be distinguished. First, the Chinese manufacturer: product information, post-market data and investigation conclusions may appear in public materials, although it is not the legal applicant. Second, an Australian affiliate or local partner: if it acts as sponsor, public information will be directly attributed to it, and it will be responsible for responding to resulting inquiries.

Timeline: A Seven-Week Window and Two Briefings

The start date is 13 August 2026. The consultation period ends on 2 October 2026, a total of seven weeks. Once the window closes, the remaining steps are review and publication of results.

On 15 September 2026, the regulator added two online briefing sessions: one at 12:00 noon Australian Eastern Time and one at 18:00 in the evening. The presenter was Tania Ahmed, Assistant Director in the medical device post-market review area. The official description was direct: to introduce the consultation, explain the proposed changes, and explain the benefits of those changes for users, including device consumers. Both sessions were scheduled on the same day around the same proposal. The schedule suggests the regulator wants industry and the public to understand the proposal before submitting comments.

Current Law Opens Only Three Narrow Doors

To understand the proposal, it is necessary to see how narrow the current gateway is. Section 61 of the Therapeutic Goods Act 1989 allows information to be published in specified circumstances. The consultation portal breaks “specified” into three categories:

• There is already a legislative instrument specifying the scope of information that may be made public.
• The regulator has already made a regulatory decision about a specific device.
• Publication is necessary to ensure the safe use of the device.

Outside these three situations, information generally cannot be provided to external parties other than the manufacturer and sponsor. The key restriction is not simply whether publication is possible, but whether there is a legal basis for publication.

The official portal acknowledges that these restrictions created real obstacles during the COVID-19 pandemic. At that time, sharing certain device safety, quality or performance information required repeated coordination with sponsors, manufacturers and health authorities. The pandemic has passed, but the restrictions remain. Even after regulatory action is complete, information is still difficult to disclose.

The Two Questions the Regulator Is Actually Asking

The portal narrows the scope of consultation to two questions:

• Should information about devices that have been included in a post-market review or investigation be made public?
• What types of information should be made public during or after a review or investigation?

One question asks whether; the other asks what. They appear simple but are not light in practice. The answer to the second will determine whether the public later sees only “a certain device model is under review” or also the review findings, affected batches and actions taken. The difference is substantial.

The portal also contains a passage that is easy to overlook. The intended meaning is that where a device has been investigated and ultimately no action is needed, or the device itself is compliant, the regulator considers that this information should also be made known to the public. Two reasons are given. For consumers, disclosure increases transparency and public trust in the regulatory system. For manufacturers and sponsors, disclosure may reduce administrative burden: information would already be on the official website and would not need to be requested separately each time.

The point of this passage is to remove “having been reviewed” from a negative list. In reality, the market often reacts differently. When customers and distributors see the words “under review,” their first instinct is often to assume the worst. The regulator wants to turn this into neutral information: it was reviewed, no problem was found, and that fact itself can be stated. Whether it can be made neutral depends on how disclosure is worded. The regulator has not provided a template for this.

A Broader Layer: This Is Not an Isolated Action

This proposal sits under Australia’s Medical Device Action Plan published in 2019. That plan is a three-part strategy to strengthen Australia’s regulatory framework for devices, including in vitro diagnostics, with a focus on the patient perspective and on using greater transparency to earn public confidence in device regulation.

Further up, the World Health Organization’s global benchmarking framework treats transparency as a capability requirement: regulators should have sound mechanisms to communicate with healthcare professionals and the public and to be transparent. The framework also seeks to promote regulatory reliance and recognition between countries. Information disclosure is moving from “good practice” to “something assessed.”

There was also an earlier trial. Before this consultation, the regulator had conducted a separate consultation on “publishing information to manage medical device supply interruptions,” with results published on the same portal. The regulator is laying this path section by section, not completing it all at once.

Source Boundaries: What Is Certain and What Is Not

What is certain: the consultation window, the two questions, and the three circumstances in the current law. These can all be traced to official pages.

What is not certain includes at least three things. First, which section will be amended and how; no draft legislative text has been published. Second, no list of information types has been provided; the second question is itself open-ended. Third, no timetable has been given: after 2 October 2026, there will be review, consolidation of results, formulation of recommendations, and then legislative process. How long each step will take is currently unclear.

Until these matters are settled, any statement that “Australia will disclose all medical device information” is not supported. Section 61 remains in force, and compliance requirements have not changed.

Source and Application Notes

Sources (official pages):

• TGA: “Consultation on improving the sharing of information about medical devices,” published 13 August 2026. https://www.tga.gov.au/news/news-articles/consultation-improving-sharing-information-about-medical-devices
• World Health Organization (WHO): “Global Benchmarking Tools.” https://www.who.int/tools/global-benchmarking-tools

Verification scope and access date: This article verified the two official sources above and cross-checked the TGA public consultation portal page “Sharing more information about medical devices” and the 15 September 2026 online briefing page. Access date: 27 September 2026 (Asia/Shanghai). The conclusions in the main text are drawn only from official public texts and do not use secondary media reports.

Application note: This article is an interpretation of public regulatory information and does not constitute a conclusion or commitment for any specific product, company or registration application. Specific requirements should be based on the current regulations and guidance published by the target country’s regulator. Information may change with subsequent official updates.

AIMEILI Regulatory Interpretation and Business Impact

What This Means for Medical Device Companies

When TGA or WHO publishes updates of this kind, companies should first determine whether the information concerns regulatory policy, guidance standards, recalls and safety, product performance, quality systems or post-market regulatory information. Different types affect registration pathways, technical files, labels and instructions for use, risk management and market maintenance differently. It should not be treated simply as industry news.

For Chinese medical device companies, the key is to convert the news into executable compliance actions: confirm whether similar products, similar technology routes or similar risk points are involved; check whether existing documents still support target market requirements; and, where necessary, update risk management, performance verification, clinical evaluation, labels and instructions for use, distributor communications and post-market surveillance records.

Which Documents Should Companies Prioritize?

Companies should prioritize checking intended use, classification basis, ISO 13485 quality system evidence, risk management documents, performance verification data, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents and existing registration certificates.

Common Risks

Common risks include unclear classification determinations, incomplete evidence chains, non-localized labels and instructions for use, unclear responsibilities of authorized representatives, and insufficient post-market maintenance arrangements.

AIMEILI View

What it means for companies. The first layer of impact falls on reputation management. It does not create new compliance obligations.

The proposal does not change registration obligations or add approval steps. It changes information flow: from “only the parties know” to “the public can check.” For companies already doing business in Australia, it adds another public-opinion channel to monitor.

In Australia, a device enters the market through inclusion in the ARTG. The applicant for that entry is the Australian sponsor. If the proposal is implemented, the first party named would not be the overseas factory, but the ARTG entry and the sponsor and manufacturer attached to it.

For Chinese companies, two identities should be separated. One is the Chinese manufacturer: product information, post-market data and investigation conclusions may appear in public materials. The other is an Australian affiliate or local partner: if it acts as sponsor, public information will directly land on it, and it will be responsible for responding to the resulting inquiries.

What Happens If You Do Nothing

Consider a Chinese company that already holds three ARTG entries in Australia, and one product enters a post-market review. The conclusion is compliant, with no action required. Under current rules, this would essentially not be disclosed. Under the direction of the proposal, the regulator could place this information into public materials after the review. Distributors, hospital procurement teams and end users could all see it. The product was not found to have a problem, but the fact that it “was reviewed” becomes part of the public record.

What must be managed is not a penalty, but an explanation. Going one level deeper: if the disclosed information includes device models, affected batches or specific descriptions of findings, the accuracy of wording becomes a new risk point. If the wording is ambiguous, the market may first interpret it in the worst way.

What to Do Now

First, identify whether you are within the review horizon. Implantable devices, software devices, and products with frequent complaints or recall history are clearly more likely to be included in reviews. Such companies should now consolidate post-market data into a consistent position, rather than discovering at the time of disclosure that they do not have a unified statement.

Second, decide in advance “who speaks and how.” Once a product enters public view, who is responsible for responding and under what position should ideally be written down now, rather than assembled after the event.

Returning to the window itself: feedback in this round will form the basis for drafting legislative text. After 2 October 2026, comments can only wait for the next round. To let the regulator hear industry views on “what level of detail should be disclosed” and “how review conclusions should be worded,” submitting now is what counts.

Whether to submit is a commercial judgment, depending on the weight of the Australian market in your portfolio. If Australia is only an incidental stop, with slow product iterations and few complaints, you may wait to see the final legislative text. But one thing does not require discussion: see the facts clearly. Whether you may be named and whether you should comment are two independent questions.

In emerging-market registration work, we often see companies focus only on the registration pathway and ignore post-market information flow. This Australian consultation reminds the industry of the second half: after the certificate is obtained, is information still yours to control?

FAQ

Can the TGA consultation on public disclosure of medical device review information be used directly as a basis for submission?

No. This article is for preliminary understanding and project assessment. Formal submissions must still be based on the latest requirements of the target country’s regulator, product classification conclusions and the company’s actual documentation.

What should companies do first after seeing a relevant update?

Companies should first conduct a documentation gap assessment to confirm whether the update affects the registration pathway, technical file, labeling, quality system or post-market maintenance.

Content Review and Application Boundaries

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations and public regulatory materials; industry media and project experience are used only as supporting judgment.

Application boundary: This article is for preliminary understanding, document preparation and project planning. It does not replace the formal requirements, testing conclusions or legal opinions of the target country’s regulator.